Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FINANCE ROUNDUP: Will VC Be Last Man Standing If Biotech Bubble Bursts?

This article was originally published in Scrip

Executive Summary

The bad news about the rapid rise in biotechnology company valuations? It will end eventually. The good news? While initial public offerings may no longer be an option for some pre-commercial companies to fund drug development, several venture capital investors recently raised new funds to back biotech startups and support follow-on financing rounds.

Advertisement

Related Content

Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms
Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth
Venture Funding Deals: $688.8m In Financings From Avitide To Zai Lab
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel